Furthermore, we confirmed that CD19@NP/17-DMAG plus imatinib treatment increased MHC-I expression in BCR-ABL1+ B-ALL cells compared to treatment with 17-DMAG plus imatinib or the vehicle control (Figures 6L-M). This evidence concerns the gene CD19 and acute lymphoblastic leukemia.